ILMN · NASDAQ · Life Sciences Tools & Services
Life Sciences Tools & Services company based in San Diego, California.
Last close, Oct 1, 2026
$265.72
Adjusted for splits and dividends
Last 12 months
+159.8%
S&P 500 +14.3% over the same dates
Market value
$40.1B
Last close × shares outstanding
Bets against the stock: 10.6M shares sold short (7.0% of shares outstanding), +8.9% vs the previous count, 5.6 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
69 sales
$436M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$4.34B
-0.7% vs the year before
Net income, fiscal 2025
$850M
As reported in the annual filing
Shares outstanding
151M
As of Jul 24, 2026
In fiscal 2025 the company spent $742M buying back its own shares. Cash actually paid, from its cash-flow statement.
A board member of Illumina, Inc. told the SEC they plan to sell $32M of Illumina, Inc. shares around Sep 4, 2026. The shares did not come from their pay. That is a tiny part of all Illumina, Inc. shares.
Stock since the trade +24.6% · S&P 500 -0.1% · to Oct 1Traded 34 days after resultsStock 134% above its 52-week low and 6% below its high, after a 12% rise in the previous month
1.03M → 976K shares held−6% of their stake
A board member of Illumina, Inc. sold $12.3M of Illumina, Inc. shares. Nobody planned it ahead of time.
Stock since the trade +21.8% · S&P 500 -0.8% · to Oct 1Traded 36 days after resultsStock within 5% of its 52-week high, after a 12% rise in the previous month
882K → 782K shares held−11% of their stake
A board member of Illumina, Inc. sold $22M of Illumina, Inc. shares. Nobody planned it ahead of time.
Stock since the trade +19.9% · S&P 500 -1.2% · to Oct 1Traded 35 days after resultsStock within 3% of its 52-week high, after a 13% rise in the previous month
944K → 930K shares held−2% of their stake
A board member of Illumina, Inc. sold $3.08M of Illumina, Inc. shares. Nobody planned it ahead of time.
Stock since the trade +19.9% · S&P 500 -1.2% · to Oct 1Traded 35 days after resultsStock within 3% of its 52-week high, after a 13% rise in the previous month
920K → 906K shares held−1% of their stake
A board member of Illumina, Inc. sold $3.01M of Illumina, Inc. shares. Nobody planned it ahead of time.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
A securities lawsuit naming the company as a defendant was filed on Dec 21, 2023 in the U.S. District Court, S.D. California. A filing is an allegation, not a finding.
Louisiana Sheriffs' Pension & Relief Fund v. Illumina, Inc., 3:23-cv-02328A securities lawsuit naming the company as a defendant was filed on Dec 21, 2023 in the U.S. District Court, S.D. California. A filing is an allegation, not a finding.
Roy v. Illumina, Inc., 3:23-cv-02327A securities lawsuit naming the company as a defendant was filed on Nov 10, 2023 in the U.S. District Court, S.D. California. A filing is an allegation, not a finding.
Kangas v. Illumina, Inc., 3:23-cv-02082Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.
Capital World Investors
Schedule 13G: passive · filed May 14, 2026 · 15.8M shares
Vanguard Capital Management
Schedule 13G: passive · filed Apr 30, 2026 · 7.94M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
9 notices filed with state agencies, covering 63 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
34 certified in FY2026 Q3, vs 42 a year earlier. 34 positions in total, median offered wage $135K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
0 approvals or clearances and 1 recall recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Last 12 months, adjusted daily closes
Adjusted close went from $102.26 on Oct 1, 2025 to $265.72 on Oct 1, 2026 (+159.8%). Disclosed trades in the last 12 months: 2 insider purchases, 112 insider sales, 2 Congress purchases, 2 Congress sales.
Short sale volume: 57.1% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 60.9%. FINRA daily files, to Oct 2, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
